Company intelligence / Profile preview

Exeliom Biosciences

Dijon, Bourgogne-Franche-Comté, Franceexeliombio.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

EXL01, the company's lead candidate, is currently in Phase 2 clinical trials across multiple therapeutic areas. It's a NOD2-dependent immune modulator being evaluated in three Phase 1/2 studies for gastric cancer, NSCLC, and HCC, with results expected in 2027. A fourth trial in RCC is planned to launch in the U.S. in 2025. EXL01 is also in Phase 2 studies for Crohn's disease and preventing recurrent C. difficile infections.

Therapeutic areas: GastroenterologyOncologyInfectious Diseases
Modalities: Live BiotherapeuticsMicrobiome-based immunotherapy
Industry: Biotech

Drug pipeline

3 assets

exl01

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Exeliom Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exeliom Biosciences.

Explore the full profile